Author

Ruijia Wang

ORCID 0000-0003-1884-0465Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:benchmarking· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1 Research Focus:software / tool· 1

Frequent Co-Authors

Huan Qiu· 2 shared Huanying Gary Ge· 2 shared John R. LydeardiD· 2 shared Tirtha ChakrabortyiD· 2 shared Amanda L. Halfond· 1 shared Antonino MontalbanoiD· 1 shared Eric Gunnar Anderson· 1 shared Hannah MageriD· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMolecular Biology

Huan Qiu

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Molecular BiologybioRxivPreprintSep 13, 2025

Cutting Through the Artifacts: Dissecting gRNA Impurities with FUSS-seq

Antonino Montalbano, Huan Qiu, Lakshmi Karthik…·Eric Gunnar Anderson

The paper identifies sequencing artifacts in gRNA purity assessment and introduces FUSS-seq to reduce them, improving accuracy for CRISPR-based therapeutics.

DOI 10.1101/2025.09.13.676056

experimental assaybenchmarking

𝕏 PostBluesky

Cancer BiologybioRxivPreprintAug 21, 2025

Integrating Human Genetics and Protective Genome Editing to Enable ADGRE2-Directed AML Therapy

Yonina Keschner, Julia Etchin, Mariana Camoesas Silva…·John R. Lydeard

This study evaluates ADGRE2 as an AML target, showing efficient gene editing in HSPCs to protect against myelotoxicity and developing ADGRE2-specific CAR T cells for therapy.

DOI 10.1101/2025.08.21.671614

humangenetic perturbation / CRISPR

𝕏 PostBluesky